Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

GLP-1 receptor agonists such as the popular weight loss/diabetes therapies Mounjaro, developed by Eli Lilly (NYSE:LLY), and ...

GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly ...

CheqUp said it had experienced a spike in interest from consumers wanting to switch or begin taking the medication.

This is all you need to know about the new weight loss jab 'Reta' that's said to be 3 times stronger than Ozempic.

Terence Stamp, best known for his role playing the villain General Zod in the blockbuster films Superman and Superman II, has ...

Viking Therapeutics (VKTX 5.71%) fell a whopping 39.2% from their previous close on Tuesday, Aug. 19. Investors were reacting ...

A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits ...

Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.

The manufacturer of Ozempic (and other Semaglutide brands) faces over $2 billion in lawsuits filed by over 1,800 patients claiming blindness, stomach paralysis, and more.

Novo Nordisk announced Monday that U.S. patients can now get a month's supply of Ozempic, the blockbuster diabetes drug, for ...